KẾT QUẢ CHUYỂN PHÔI TRỮ NHÓM BỆNH NHÂN HỘI CHỨNG BUỒNG TRỨNG ĐA NANG CHUẨN BỊ NIÊM MẠC TỬ CUNG BẰNG LETROZOLE

Abstract

Objective: This study aimed to evaluate the outcomes of frozen embryo transfer (FET) in patients with polycystic ovary syndrome (PCOS) whose endometrium was prepared using an aromatase inhibitor protocol. Methods: A cross-sectional descriptive study was conducted on 97 PCOS patients undergoing their first FET cycle at the Assisted Reproductive Technology Center, Hanoi Hospital, from June 2024 to June 2025. All patients underwent endometrial preparation with Letrozole at a dose of 5 mg/day for 5 consecutive days, starting on day 2–3 of the menstrual cycle. When a dominant follicle measuring 18–20 mm was observed, 10,000 IU of hCG was administered, followed by luteal phase support with vaginal micronized progesterone. Blastocyst transfer was performed five days after initiating progesterone. Transfer outcomes were assessed based on endometrial thickness, biochemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate, miscarriage rate, and ectopic pregnancy rate. Results: The biochemical pregnancy rate was 10.3%, clinical pregnancy rate was 53.6%, ongoing pregnancy rate was 48.5%, miscarriage rate was 4.1%, and ectopic pregnancy rate was 1%. Conclusion: Endometrial preparation using an aromatase inhibitor protocol demonstrated relatively high clinical pregnancy rates (53.6%) among PCOS patients. This protocol may represent a viable option in clinical practice to improve treatment outcomes in this patient population.